Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis.

Cancers (Basel) · 2022 · PMC8996856 · PMID 35406413

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

borderline significancep = 0.06so close (0.05 < p ≤ 0.1)

First, our data demonstrated anti-EGFR re-exposure to be associated with a distinctly higher OS, although only with borderline significance ( p = 0.06), and high response rates to retreatment.

also in 7,017 other papers

showed a trendno p-value reported

Similarly, median PFS for the last anti-EGFR-based therapy showed a trend towards a shorter mPFS in the rechallenge patients compared to the reintroduction patients without statistical significance (3.68 vs. 7.33 months, n.s.). 4.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.